DEC 23, 2019 9:46 AM PST

Eye Solution Approved for Surgical Application

WRITTEN BY: Nouran Amin

As announced by the Dutch Ophthalmic Research Center in a press release, a new eye solution was recently approved by the US Food and Drug Administration for surgical application. The dye is called Brilliant Blue G ophthalmic solution and is used for staining the internal limiting membrane (ILM) of the eye.

“Brilliant Blue G, intended to stain and distinguish the ILM from the retina to facilitate removal, will be the first FDA-approved product for this indication,” the release said.

Although the Brilliant Blue G (BBG) ophthalmic solution has been in use for staining for internal limiting membrane (ILM) in Europe during the past decade, no commercial formulation was approved by the FDA. Instead, an off-label indocyanine green (ICG) was the common used dye utilized for staining the ILM in the United States.

Studies have addressed differences in visual outcomes that are more improved with the BBG as opposed with the ICG. Furthermore, clinical and library analyses confirmed that there retinal toxicity with ICG use including cell death. In addition, BBG utilizes polyethylene glycol and has a high attachment rate to ILM as opposed to another membrane known as epiretinal membrane (ERM) which allows BBG to function as a negative stain for ERM. The BBG staining and ophthalmic solution also increases ILM rigidity and can aid in ILM peeling with more efficacy and safety and potentially produce better patient outcomes.

Learn more about ILM peeling:

“DORC has always worked closely with surgeons around the world to develop practical advancements in treating eye disorders” Thierry Leclercq, CEO of DORC International, said in the release. “The Brilliant Blue G ophthalmic solution submission is just another example of DORC responding to market needs. We look forward to working with the FDA throughout the review process.”

Source: Healio.com

 

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 06, 2021
Infographics
Psychedelic Medicine 101
APR 06, 2021
Psychedelic Medicine 101
As clinical trials for psychedelics progress, interest in psychedelics is increasing among pharmaceutical firms, clinici ...
APR 01, 2021
Immunology
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
APR 01, 2021
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
Cancer researchers have developed a therapeutic vaccine for melanoma, a deadly form of skin cancer. Instead of protectin ...
APR 27, 2021
Cannabis Sciences
CBD Doesn't Reduce Pain, but Makes it Less Unpleasant
APR 27, 2021
CBD Doesn't Reduce Pain, but Makes it Less Unpleasant
While anecdotal reports tout cannabidiol’s (CBD) utility for pain relief, up until now, there’s been limited ...
MAY 03, 2021
Drug Discovery & Development
Low Dose Radiation May Improve Symptoms of Alzheimer's
MAY 03, 2021
Low Dose Radiation May Improve Symptoms of Alzheimer's
While high doses of radiation are known to be harmful, low doses may be able to help the body protect and repair. And no ...
MAY 22, 2021
Drug Discovery & Development
FDA Approves Trials for Ketamine to Treat Parkinson's
MAY 22, 2021
FDA Approves Trials for Ketamine to Treat Parkinson's
The US FDA has approved PharmaTher’s Investigational New Drug application to begin Phase 2 clinical trials for ket ...
JUN 18, 2021
Drug Discovery & Development
FDA Approves First New Drug Since 2014 for Weight-loss
JUN 18, 2021
FDA Approves First New Drug Since 2014 for Weight-loss
A new medication called ‘Wegovy’ produced by Novo Nordisk has been approved by the Food and Drug Administrat ...
Loading Comments...